Physician profile
Robert Colucci
NPI 1306918339
$144,162.99
in general payments reported to CMS, 2019-2025
16 companies · $2,193 in 2025
The $2,193 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $14K · 2021: $26K · 2022: $33K · 2023: $36K · 2024: $6,730 · 2025: $2,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $5,480 · Travel and Lodging: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,870.00 |
| Food and Beverage | $5,479.78 |
| Travel and Lodging | $3,058.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $138,272.69 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,873.96 | 2019-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $1,152.73 | 2019-2025 | |
| Axsome Therapeutics, INC. | $566.76 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $514.83 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $346.29 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $295.51 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $246.25 | 2024-2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $239.34 | 2023 | Spravato |
| Abbvie INC. | $221.46 | 2024-2025 | |
| Indivior INC. | $171.84 | 2019 | |
| Corium, LLC | $82.20 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $82.06 | 2024-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $54.11 | 2019 | |
| Tris Pharma INC | $23.50 | 2025 | Dyanavel Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $19.46 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Colucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.